[
    {
        "content": "* Perrigo Company PLC reports third quarter 2017 financial results",
        "date": "11092017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Q3 GAAP EPS $0.31 "
    },
    {
        "content": "* Perrigo announces tentative fda approval for a first-to-file generic version of Picato Gel 0.05 pct",
        "date": "11022017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces tentative FDA approval for a first-to-file generic version of Picato Gel 0.05 pct "
    },
    {
        "content": "* Perrigo announces tentative FDA approval for a first-to-file generic version of Picato Gel .015%",
        "date": "10242017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces tentative FDA approval for generic version of Picato gel.015% "
    },
    {
        "content": "* Perrigo announces patent litigation settlement for the generic version of Onexton\u00ae Gel",
        "date": "10262017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces patent litigation settlement for generic version of Onexton\u00ae Gel "
    },
    {
        "content": "* Perrigo announces FDA final approval for its AB rated generic version of Exalgo\u00ae 32mg extended release tablets",
        "date": "09212017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces FDA final approval for its AB rated generic version of Exalgo\u00ae 32mg extended release tablets "
    },
    {
        "content": "* Perrigo announces tentative FDA approval for the generic version of Acanya\u00ae gel",
        "date": "09182017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces tentative FDA approval for generic version of Acanya gel "
    },
    {
        "content": "* Perrigo announces final FDA approval and settlement for the store brand OTC equivalent of Nexium 24hr capsules",
        "date": "08212017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces final FDA approval and settlement for the store brand OTC equivalent of Nexium 24hr capsules "
    },
    {
        "content": "* Perrigo announces FDA final approval for its AB rated generic version of mycolog\u00ae II cream",
        "date": "08162017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces FDA final approval for its AB rated generic version of mycolog\u00ae II cream "
    },
    {
        "content": "* Sets quarterly dividend of $0.16per share Source text for Eikon: Further company coverage:",
        "date": "08082017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company sets quarterly dividend of $0.16/share "
    },
    {
        "content": "* Perrigo announces tentative FDA approval for generic version of Mirvaso gel",
        "date": "08042017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces tentative FDA approval for generic version of Mirvaso "
    },
    {
        "content": "* Perrigo says Rx segment  year-over-year price erosion assumption remains at 9 percent to 11 percent - Conf Call",
        "date": "08102017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo says Rx segment  year-over-year price erosion assumption remains at 9 pct to 11 pct "
    },
    {
        "content": "* SK Capital announces agreement to acquire Perrigo Company plc\u2019s active pharmaceutical ingredients business",
        "date": "08102017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-SK Capital announces deal to acquire Perrigo Company plc\u2019s active pharmaceutical ingredients business "
    },
    {
        "content": "* Perrigo announces the launch of the AB rated generic version of Transderm Scop 1.5 mg",
        "date": "07312017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces the launch of the AB rated generic version of Transderm Scop 1.5 mg "
    },
    {
        "content": "Perrigo Co Plc's  shares surged as much as 20.4 percent on Thursday after the drugmaker surprised Wall Street with strong quarterly generic drug sales due to new product launches and raised its full-year adjusted profit forecast.",
        "date": "08102017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo's strength in generics surprises investors  shares soar "
    },
    {
        "content": "* Shares rise as much as 20.4 pct (Adds conference call details; updates shares)",
        "date": "08102017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 1-Perrigo's strength in generics surprises investors  shares soar "
    },
    {
        "content": "* Perrigo - In connection with workforce reduction plan  estimates it will recognize total pre-tax restructuring charges of about $55 million to $65 million",
        "date": "08102017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo updates on restructuring charges related to its workforce reduction plan "
    },
    {
        "content": "* Perrigo company plc reports second quarter 2017 financial results",
        "date": "08102017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Q2 loss per share $0.49 "
    },
    {
        "content": "* Perrigo company plc says  on march 8  2017  remuneration committee of board approved changes to acting cfo ronald winowiecki's compensation",
        "date": "07212017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo says board suspends CFO search during search for John Hendrickson's successor as CEO - SEC Filing "
    },
    {
        "content": "* Perrigo announces settlement of generic version of dymista nasal spray patent litigation",
        "date": "07172017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces settlement of generic version of dymista nasal spray patent litigation "
    },
    {
        "content": "* Perrigo confirms patent challenge for generic version of Soolantra cream  1%",
        "date": "07172017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo confirms patent challenge for generic version of Soolantra cream  1 pct "
    },
    {
        "content": "* Perrigo launches the generic version of Axiron\u00ae Topical Solution Source text for Eikon: Further company coverage:",
        "date": "07052017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo launches the generic version of Axiron Topical Solution "
    },
    {
        "content": "* Perrigo announces FDA final approval for its first-to-file AB rated generic version of androgel\u00ae topical gel  1.62% packets",
        "date": "07172017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces FDA final approval for its first-to-file AB rated generic version of Androgel "
    },
    {
        "content": "* Search process for CEO is being overseen by board's nominating and governance committee Source text for Eikon: Further company coverage:",
        "date": "06212017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo retains Spencer Stuart for CEO search "
    },
    {
        "content": "* Perrigo announces the launch of generic equivalents to Derma-Smoothe/FS scalp oil and body oil Source text for Eikon: Further company coverage:",
        "date": "06212017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo launches generic equivalents to Derma-Smoothe/FS scalp oil and body oil "
    },
    {
        "content": "* Perrigo company plc announces pricing for its cash tender offer",
        "date": "06142017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company announces pricing for its cash tender offer "
    },
    {
        "content": "* Perrigo Company Plc announces early tender results for cash tender offer",
        "date": "06142017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company announces early tender results for cash tender offer "
    },
    {
        "content": "June 5 Generic drugmaker Perrigo Company Plc said on Monday that Chief Executive John Hendrickson planned to retire.",
        "date": "06052017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Drugmaker Perrigo's CEO to retire "
    },
    {
        "content": "* Perrigo Company Plc says CEO John Hendrickson's FY 2016 total compensation was $5.8 million - SEC filing",
        "date": "06072017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo says CEO John Hendrickson's FY 2016 total compensation was $5.8 mln - SEC filing "
    },
    {
        "content": "* Perrigo announces forthcoming retirement of CEO John Hendrickson",
        "date": "06052017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo reports forthcoming retirement of CEO Hendrickson "
    },
    {
        "content": "* Perrigo Company PLC says CEO John Hendrickson's FY 2016 total compensation was $5.8 million",
        "date": "06072017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company Plc says CEO John Hendrickson's FY 2016 total compensation was $5.8 million "
    },
    {
        "content": "* Perrigo Company Plc announces $1 400 000 000 cash tender offer for certain notes",
        "date": "05312017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company announces $1.4 bln cash tender offer for certain notes "
    },
    {
        "content": "* Perrigo Company PLC files first quarter 2017 form 10-Q and reports first quarter 2017 financial results",
        "date": "05302017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company reaffirms FY17 adj EPS view $4.15 to $4.50 "
    },
    {
        "content": "* Perrigo Company Plc says CEO John T . Hendrickson's 2016 total compensation $5.8 million - sec filing",
        "date": "05232017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company says CEO John Hendrickson's 2016 total compensation $5.8 mln "
    },
    {
        "content": "* Perrigo files 2016 form 10-k with restated financial statements; reports fourth quarter and calendar year 2016 financial results; announces 2017 annual meeting date",
        "date": "05222017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo files 2016 form 10-k with restated financial statements "
    },
    {
        "content": "* Takes share stake of 1.7 million shares in Perrigo Co Plc - SEC filing",
        "date": "05152017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Greenlight Capital takes share stake in Perrigo  cuts share stake in Time Warner "
    },
    {
        "content": "* Perrigo Company plc files for non-timely 10-Q - sec filing Source text (http://bit.ly/2q9PsRA) Further company coverage:",
        "date": "05112017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company Plc files for non-timely 10-Q "
    },
    {
        "content": "* Perrigo company plc - new directors nominated by starboard in accordance with previously announced agreement",
        "date": "05082017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces appointment of Rolf Classon  Adriana Karaboutis to co's board "
    },
    {
        "content": "* Sets quarterly dividend of $0.16per share Source text for Eikon: Further company coverage:",
        "date": "05032017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo sets quarterly dividend "
    },
    {
        "content": "* Search warrants were executed at company's corporate offices associated with an ongoing investigation by U.S. Department of Justice Antitrust Division related to drug pricing",
        "date": "05032017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo says search warrants were executed at company's corporate offices "
    },
    {
        "content": "* Perrigo Company Plc - effective April 19  company's board appointed Ronald L. Winowiecki as company's principal accounting officer",
        "date": "04252017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company Plc appoints RONALD L. WINOWIECKI as  principal accounting officer "
    },
    {
        "content": "* Perrigo announces restatement of previously issued forms 10-k and 10-q financial statements; announces select preliminary unaudited first quarter 2017 financial results",
        "date": "04252017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Sees FY 2017 sales $4.6 billion to $4.8 billion "
    },
    {
        "content": "* Perrigo completes divestiture of Tysabri\u00ae royalty stream for up to $2.85 billion  Source text for Eikon:  Further company coverage:",
        "date": "03272017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo completes divestiture of tysabri royalty stream for up to $2.85 billion "
    },
    {
        "content": "* Perrigo Company Plc-  announced first-to-market launch of over--counter store brand equivalent to women's Rogaine foam  Source text for Eikon:  Further company coverage:",
        "date": "03082017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announced first-to-market launch of OTC store brand equivalent to women's Rogaine foam "
    },
    {
        "content": "* Perrigo announces FDA final approval for the generic version of Axiron topical solution  30 mg/1.5 ml  Source text for Eikon: Further company coverage:",
        "date": "03012017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces FDA final approval for the generic version of Axiron topical solution "
    },
    {
        "content": "* Perrigo Company Plc - in process of identifying certain deferred tax assets and other related effects at Omega Pharma Invest N.V.",
        "date": "03072017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo says in process of identifying certain deferred tax assets  other related effects at Omega Pharma Invest N.V "
    },
    {
        "content": "* Sets quarterly dividend of $0.16 per share  Source text for Eikon:  Further company coverage:",
        "date": "02212017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo sets quarterly dividend of $0.16 per share "
    },
    {
        "content": "* Perrigo Company Plc - company expects to reduce its global workforce by approximately 750 employees",
        "date": "02272017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company expects to reduce its workforce by about 750 employees "
    },
    {
        "content": "* Perrigo signs agreement to divest tysabri\u00ae royalty stream for up to $2.85 billion",
        "date": "02272017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo signs agreement to divest tysabri royalty stream for up to $2.85 billion "
    },
    {
        "content": "* Perrigo Company Plc - Is in the process of identifying certain deferred tax assets and other related effects at Omega Pharma Invest N.V.",
        "date": "02272017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company Plc files for non-timely 10-Q "
    },
    {
        "content": "* Is conducting a thorough search process to identify a permanent Chief Financial Officer  which includes Mr. Winowiecki as a key candidate",
        "date": "02272017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo says Ron Winowiecki appointed acting CFO "
    },
    {
        "content": "* Perrigo announces FDA final approval for hydrocodone bitartrate and homatropine methylbromide oral solution  Source text for Eikon:  Further company coverage:",
        "date": "02172017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces FDA final approval for hydrocodone bitartrate and homatropine methylbromide oral solution "
    },
    {
        "content": "Drugmaker Perrigo Co Plc struck a deal on Tuesday with Starboard Value LP  agreeing to add three directors to the board as the activist hedge fund ramps up pressure on the company.",
        "date": "02082017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Perrigo adds three directors in deal with activist Starboard "
    },
    {
        "content": "* Has filed an abbreviated new drug application with U.S. Food and Drug Administration for Clindamycin",
        "date": "02072017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo company has filed an abbreviated new drug application with U.S. FDA for Clindamycin "
    },
    {
        "content": "Feb 7 Drugmaker Perrigo Co Plc struck a deal on Tuesday with Starboard Value LP  agreeing to add three directors to the board as the activist hedge fund ramps up pressure on the company.",
        "date": "02082017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "REFILE-UPDATE 2-Perrigo adds three directors in deal with activist Starboard "
    },
    {
        "content": "* Company to reconstitute board with five new independent directors",
        "date": "02072017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces agreement with Starboard "
    },
    {
        "content": "Feb 7 Perrigo Co Plc said it has entered an agreement with Starboard Value LP  which owns about 6.7 percent of Perrigo's shares  regarding the membership and composition of the drugmaker's board.",
        "date": "02072017",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo adds Starboard CEO to its board "
    },
    {
        "content": "* Perrigo announces fda approval of its first-to-file ab rated generic version of topicort\u007f spray  0.25%",
        "date": "01242017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces FDA approval of its first-to-file ab rated generic version of Topicort spray "
    },
    {
        "content": "* Changed its reporting segments to better align with company's organizational structure.",
        "date": "01102017",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo updates segment reporting structure "
    },
    {
        "content": "* Starboard Value LP - purchased Perrigo shares based on belief that shares  when purchased  were undervalued - SEC filing",
        "date": "11152016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Starboard Value reports 6.2 pct stake in Perrigo as of Nov 3 "
    },
    {
        "content": "* Greenlight Capital Inc takes share stake of 287 133 shares in Geo Group Inc",
        "date": "11142016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Greenlight Capital ups share stake in Aercap Holdings  dissolves in Perrigo Co Plc "
    },
    {
        "content": "* Jana Partners LLC takes sole share stake of 111 127 shares in Sage Therapeutics Inc",
        "date": "11142016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Jana Partners cuts sole share stake in Alphabet  takes sole share stake in Mondelez International "
    },
    {
        "content": "* Sets quarterly dividend of $0.145 per share  Source text for Eikon:  Further company coverage:",
        "date": "11082016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo sets qtrly dividend of $0.145/shr "
    },
    {
        "content": "* CEO says Perrigo to initiate claim arbitration against sellers of Omega which we plan to do before the end of this year",
        "date": "11102016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo CEO says seeking \"bolt-on\" acquisitions: Conf Call "
    },
    {
        "content": "Perrigo Co Plc reported a higher-than-expected adjusted quarterly profit and said it would review strategic options for royalty rights from sales of multiple sclerosis drug Tysabri.",
        "date": "11102016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo to review options for Multiple Sclerosis drug Tysabri "
    },
    {
        "content": "* Shares up 4 pct in premarket trading   (Adds details  shares)",
        "date": "11102016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 2-Perrigo to review options for Multiple Sclerosis drug Tysabri "
    },
    {
        "content": "* Perrigo Company Plc announces appointment of two new independent directors to board",
        "date": "11102016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company Plc announces appointment of two new independent directors to board "
    },
    {
        "content": "* Perrigo Company PLc to review strategic alternatives for Tysabri\u007f royalty stream",
        "date": "11102016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company PLc to review strategic alternatives for Tysabri\u007f royalty stream "
    },
    {
        "content": "* Perrigo Company PLC reports third quarter 2016 financial results",
        "date": "11102016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company PLC reports third quarter 2016 financial results "
    },
    {
        "content": "Nov 10 Perrigo Company Plc  a maker of generic and over-the-counter drugs  said it will review strategic alternatives for the rights to the royalties from sales of its multiple sclerosis drug.",
        "date": "11102016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo to review options for multiple sclerosis drug royalties "
    },
    {
        "content": "* Co announces exclusive licensing agreement with Highland Pharmaceuticals LLC for its Tarex methamphetamine blocking technology",
        "date": "09272016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company announces licensing agreement with Highland Pharmaceuticals "
    },
    {
        "content": "Perrigo Company Plc   the manufacturer of generic drugs and over the counter medicines targeted by activist investor Starboard Value LP  is exploring a sale of the royalties from its multiple sclerosis drug Tysabri  people familiar with the matter said.",
        "date": "09162016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Perrigo explores sale of royalties of drug Tysabri: sources "
    },
    {
        "content": "Sept 16 Perrigo Company Plc  the manufacturer of generic drugs and over the counter medicines targeted by activist investor Starboard Value LP  is exploring a sale of the royalties from its multiple sclerosis drug Tysabri  people familiar with the matter said.",
        "date": "09162016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 1-Perrigo explores sale of royalties of drug Tysabri -sources "
    },
    {
        "content": "Sept 16 Perrigo Company Plc  the generic drug manufacturer targeted by activist investor Starboard Value LP  is exploring a sale of the royalties it receives from sales of multiple sclerosis drug Tysabri  people familiar with the matter said.",
        "date": "09162016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo explores sale of royalties of drug Tysabri -sources "
    },
    {
        "content": "NEW YORK Activist shareholder Starboard Value LP on Monday disclosed a 4.6 percent stake in Perrigo Co Plc  and said the Dublin-based drugmaker must make immediate improvements to turn around its sagging stock price.",
        "date": "09122016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Activist Starboard demands rapid changes at Perrigo "
    },
    {
        "content": "NEW YORK  Sept 12 Activist shareholder Starboard Value LP on Monday disclosed a 4.6 percent stake in Perrigo Co Plc and said the Dublin-based drugmaker must make immediate improvements to turn around its sagging stock price.",
        "date": "09122016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 4-Activist Starboard demands rapid changes at Perrigo "
    },
    {
        "content": "* Perrigo acknowledges receipt of letter from Starboard Value LP",
        "date": "09122016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo acknowledges receipt of letter from Starboard Value "
    },
    {
        "content": "Sept 12 Starboard Value LP disclosed a 4.6 percent stake in Perrigo Co Plc  making the activist investor one of the Dublin-based drugmaker's biggest shareholders.",
        "date": "09122016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Starboard discloses 4.6 pct stake in Perrigo  seeks changes "
    },
    {
        "content": "* Activist investor Starboard takes 4.6 pct stake in drugmaker Perrigo  worth nearly $600 million  urges Perrigo to refocus its business - CNBC  citing DJ  Further company coverage:",
        "date": "09122016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Activist investor Starboard takes 4.6 pct stake in drugmaker Perrigo- CNBC  citing DJ "
    },
    {
        "content": "* Perrigo announces tentative FDA approval for generic version of Epiduo\u007f gel  Source text for Eikon:  Further company coverage:",
        "date": "09012016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo reports tentative FDA approval for generic version of Epiduo\u007f gel "
    },
    {
        "content": "* Perrigo announces tentative FDA approval for generic version of Suprep\u007f oral solution and confirms patent challenge for generic version of Mirvaso\u007f gel",
        "date": "08232016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo - generic version of Suprep oral solution is indicated for treatment of cleansing of colon in preparation for colonoscopy in adults "
    },
    {
        "content": "* Ups share stake in Valeant Pharmaceuticals International Inc by 43.6 pct to 19.1 mln shares - SEC filing",
        "date": "08152016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Paulson & Co raises share stake in Valeant  Facebook - SEC filing "
    },
    {
        "content": "* Perrigo to acquire U.S. Distributor of Healthcare & Consumer Goods Products  Geiss  Destin & Dunn  Source text for Eikon:  Further company coverage:",
        "date": "08172016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo to acquire Geiss  Destin & Dunn "
    },
    {
        "content": "Aug 10 Perrigo Co Plc slashed its full-year earnings forecast for the second time  citing pricing pressure in its generic drugs business  sending its shares down as much as 13 percent and wiping out about $1.77 billion of market value.",
        "date": "08102016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo slashes full-year forecast again  shares plunge "
    },
    {
        "content": "* Sets quarterly dividend of $0.145 per share  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom; +1 646 223 8780)",
        "date": "08022016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company sets quarterly dividend of $0.145 per share "
    },
    {
        "content": "* Perrigo announces leadership change in Rx Pharmaceuticals segment",
        "date": "07212016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces leadership change in Rx Pharmaceuticals segment "
    },
    {
        "content": "* Perrigo announces FDA final approval and launch of the store brand equivalent to Zegerid OTC\u007f capsules",
        "date": "07182016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo says FDA approved store brand equivalent to Zegerid OTC "
    },
    {
        "content": "* Perrigo announces FDA clearance and launch of non-GMO infant formulas for the U.S. Store brand market",
        "date": "06212016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company launches non-GMO infant formulas "
    },
    {
        "content": "* Perrigo divests vitamins  minerals & supplements business to IVC  Source text for Eikon:  Further company coverage:",
        "date": "06202016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo divests vitamins  minerals & supplements business to IVC "
    },
    {
        "content": "* Has secured right to be sole authorized generic distributor should mallinckrodt elect to launch an authorized generic product",
        "date": "06162016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo says FDA approval of generic version of Ofirmev\u007f Acetaminophen injection "
    },
    {
        "content": "* U.S. FDA has approved  and that perrigo has launched  fluticasone propionate nasal spray usp  50 mcg per spray",
        "date": "05312016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo announces FDA approval of store brand equivalent to Flonase "
    },
    {
        "content": " ",
        "date": "05162016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Perrigo Company reports Q1 GAAP loss per share of $0.93 "
    },
    {
        "content": "* Says it has filed for non-timely 10-q at u.s. Sec - sec filing",
        "date": "05132016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo files for non-timely 10-Q - SEC Filing "
    },
    {
        "content": "* Perrigo announces fda approval and launch of the generic version of benzaclin\u007f pump topical gel",
        "date": "05022016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo says FDA approved generic version of benzaclin pump topical gel "
    },
    {
        "content": "* Perrigo company plc says declared a quarterly dividend of $0.145 per share",
        "date": "04262016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo company plc announces quarterly dividend of $0.145 per share "
    },
    {
        "content": "Former Perrigo Co Plc  head Joseph Papa was named Chief Executive Officer at Valeant Pharmaceuticals International  on Monday  a role in which investors said he should focus on returning the company to growth.",
        "date": "04252016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Valeant names Papa CEO after he resigns from Perrigo "
    },
    {
        "content": "* Sharon Kochan    vice president   will have expanded responsibilities that will now include  co's branded consumer healthcare",
        "date": "04282016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo says Sharon Kochan responsibilities will include co's branded consumer healthcare "
    },
    {
        "content": "April 25 Former Perrigo Co Plc head Joseph Papa was named Chief Executive Officer at Valeant Pharmaceuticals International on Monday  a role in which investors said he should focus on returning the company to growth.",
        "date": "04252016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 6-Valeant names Papa CEO after he resigns from Perrigo "
    },
    {
        "content": "Drugmaker Valeant Pharmaceuticals International Inc  is seeking to appoint Joseph Papa  Perrigo Co Plc's  boss   as its new chief executive  a source familiar with the matter said.",
        "date": "04222016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Valeant in talks to hire Perrigo's Papa as CEO: source "
    },
    {
        "content": "* In connection with Papa's resignation  he and co  and  Perrigo Michigan entered into an amendment to employment agreement",
        "date": "04252016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo enters into amendment to employment agreement in connection with Joseph Papa's resignation "
    },
    {
        "content": "* Perrigo appoints john t. Hendrickson as chief executive officer  provides preliminary first quarter 2016 selected financial results  and updates full year 2016 guidance",
        "date": "04252016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo Company appoints John T. Hendrickson as CEO "
    },
    {
        "content": "April 22 Drugmaker Valeant Pharmaceuticals International Inc is seeking to appoint Joseph Papa  Perrigo Co Plc's boss   as its new chief executive  a source familiar with the matter said.",
        "date": "04222016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 2-Valeant in talks to hire Perrigo's Papa as CEO -source "
    },
    {
        "content": "* Released statement regarding recent media coverage concerning chairman and ceo joseph c. Papa",
        "date": "04222016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo releases statement regarding media coverage of CEO "
    },
    {
        "content": "* Perrigo appoints John T. Hendrickson as chief executive officer  provides preliminary first-quarter 2016 selected financial results  and updates full-year 2016 guidance",
        "date": "04252016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo says Joseph C. Papa resigns as chairman and CEO "
    },
    {
        "content": "* We are aware of speculation regarding our Chairman and CEO Joseph Papa",
        "date": "04222016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Perrigo says aware of speculation regarding CEO  will not comment "
    },
    {
        "content": "April 21 Valeant Pharmaceuticals International Inc is seeking to name Perrigo Co Plc's Joseph Papa as its new chief executive  CNBC tweeted  citing Dow Jones.",
        "date": "04222016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Valeant wants Perrigo's Papa as its new CEO - CNBC  citing Dow Jones "
    },
    {
        "content": "YERUHAM  Israel Generic drugmaker Perrigo Co said it expected a $100 million boost to annual sales from a new factory inaugurated in Israel on Wednesday.",
        "date": "03022016",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Drugmaker Perrigo expects $100 million boost from new Israeli plant "
    },
    {
        "content": "YERUHAM  Israel  March 2 Generic drugmaker Perrigo Co said it expected a $100 million boost to annual sales from a new factory inaugurated in Israel on Wednesday.",
        "date": "03022016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Drugmaker Perrigo expects $100 mln boost from new Israeli plant "
    },
    {
        "content": "Jan 8 The hedge fund billionaire Steven A. Cohen has resolved U.S. charges related to insider trading  in an accord that clears the way for one of Wall Street's top investors to soon manage outside money even after his former firm pleaded guilty to fraud.",
        "date": "01082016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 3-Billionaire Cohen settles with SEC  could soon manage outside money "
    },
    {
        "content": "The hedge fund billionaire Steven A. Cohen has resolved U.S. charges related to insider trading  in an accord that clears the way for one of Wall Street's top investors to soon manage outside money even after his former firm pleaded guilty to fraud.",
        "date": "01082016",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Billionaire Cohen settles with SEC  could soon manage outside money "
    },
    {
        "content": "AstraZeneca  said on Monday it had finalised plans to divest its Crohn\u2019s disease drug Entocort by selling U.S. rights to the medicine to Perrigo  for $380 million.",
        "date": "11232015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "AstraZeneca sells U.S. drug rights to Perrigo for $380 million "
    },
    {
        "content": "Nov 23 AstraZeneca said on Monday it had finalised plans to divest its Crohn's disease drug Entocort by selling U.S. rights to the medicine to Perrigo for $380 million.",
        "date": "11232015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "AstraZeneca sells U.S. drug rights to Perrigo for $380 mln "
    },
    {
        "content": "Nov 16 Generic Drugmaker Mylan NV plans to buy back shares worth up to $1 billion  after Perrigo Co Plc'S shareholders spurned its $26 billion hostile bid.",
        "date": "11162015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan to buy back $1 bln in stock "
    },
    {
        "content": "* Astrazeneca enters into agreement with Perrigo for rights to Entocort \u007f in us",
        "date": "11232015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Astrazeneca  Perrigo sign deal for US rights to Entocort "
    },
    {
        "content": "Perrigo Company Plc   the Irish-based generic drugmaker trying to fend off a hostile bid by Mylan NV   held unsuccessful talks to acquire Endo International Plc  in an all-stock deal  according to people familiar with the matter.",
        "date": "11122015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Mylan-targeted Perrigo held merger talks with Endo: sources "
    },
    {
        "content": "Nov 12 Perrigo Company Plc  the Irish-based generic drugmaker trying to fend off a hostile bid by Mylan NV  held unsuccessful talks to acquire Endo International Plc in an all-stock deal  according to people familiar with the matter.",
        "date": "11122015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan-targeted Perrigo held merger talks with Endo -sources "
    },
    {
        "content": "* Perrigo shares fall as much as 10 pct   (Adds analysts comments  background; updates shares)",
        "date": "11132015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "UPDATE 3-Perrigo shareholders snub drugmaker Mylan's $26 bln hostile bid "
    },
    {
        "content": "Drugmaker Mylan NV's  $26 billion hostile bid for Perrigo Co Plc  failed on Friday  putting an end to the ongoing saga  which started more than seven months ago.",
        "date": "11132015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan fails in $26 billion takeover bid for Perrigo "
    },
    {
        "content": "Nov 13 Drugmaker Mylan NV's $26 billion hostile bid for Perrigo Co Plc failed on Friday  putting an end to the ongoing saga  which started more than seven months ago.",
        "date": "11132015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "TIMELINE-Mylan fails in $26 bln takeover bid for Perrigo "
    },
    {
        "content": "Nov 13 Mylan NV said on Friday that 40 percent of Perrigo Co Plc's shares were tendered in its $26 billion hostile takeover offer  falling short of the goal of 50 percent.",
        "date": "11132015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan says 40 percent of Perrigo shares tendered  misses goal "
    },
    {
        "content": "Generic drug maker Mylan NV's  $26 billion hostile bid for peer Perrigo Company Plc  looked unlikely to succeed late on Thursday  a few hours before it was set to expire  according to people familiar with the matter.",
        "date": "11132015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan's tender offer for Perrigo unlikely to succeed: sources "
    },
    {
        "content": "Nov 12 Generic drug maker Mylan NV's $26 billion hostile bid for peer Perrigo Company Plc looked unlikely to succeed late on Thursday  a few hours before it was set to expire  according to people familiar with the matter.",
        "date": "11132015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 1-Mylan's tender offer for Perrigo unlikely to succeed -sources "
    },
    {
        "content": "Nov 12 Generic drug maker Mylan NV's  $26-billion hostile bid for peer Perrigo Company Plc  looked unlikely to succeed  a few hours before it was set to expire  a person familiar with the matter said.",
        "date": "11132015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan's tender offer for Perrigo unlikely to succeed -source "
    },
    {
        "content": "TEL AVIV Mylan will likely win its bid to take over Irish-based generic drugmaker Perrigo Co  but if the bid fails the company can live without seeking an alternative acquisition  its chairman said on Wednesday.",
        "date": "11042015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Mylan not relying on acquisitions if Perrigo bid fails: chairman "
    },
    {
        "content": "TEL AVIV  Nov 4 Mylan will likely win its bid to take over Irish-based generic drugmaker Perrigo Co   but if the bid fails the company can live without seeking an alternative acquisition  its chairman said on Wednesday.",
        "date": "11042015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan not relying on acquisitions if Perrigo bid fails -chairman "
    },
    {
        "content": "WASHINGTON Mylan  received U.S. antitrust approval for its hostile bid for Irish-based generic drugmaker Perrigo Co   the Federal Trade Commission said on Tuesday.",
        "date": "11032015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "FTC approves Mylan's hostile bid for Perrigo with conditions "
    },
    {
        "content": "TEL AVIV  Nov 2 Shares in Mylan will begin trading in Tel Aviv on Nov. 4  the Tel Aviv Stock Exchange (TASE) said on Monday  as the generic drugmaker seeks to strengthen its hand in its hostile bid for rival Perrigo Co Plc   which is also listed on the bourse.",
        "date": "11022015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Mylan shares to begin trading in Tel Aviv on Nov. 4 "
    },
    {
        "content": "WASHINGTON Mylan  received U.S. antitrust approval for its hostile bid for Irish-based generic drugmaker Perrigo Co  under the condition Mylan sells seven drugs to Alvogen Group Inc  the Federal Trade Commission said on Tuesday.",
        "date": "11042015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "FTC approves Mylan's hostile bid for Perrigo with conditions "
    },
    {
        "content": "WASHINGTON  Nov 3 Mylan received U.S. antitrust approval for its hostile bid for Irish-based generic drugmaker Perrigo Co  the Federal Trade Commission said on Tuesday.",
        "date": "11032015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 1-FTC approves Mylan's hostile bid for Perrigo with conditions "
    },
    {
        "content": "Nov 3 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Tuesday:",
        "date": "11032015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "WASHINGTON  Nov 3 Mylan received U.S. antitrust approval for its hostile bid for Irish-based generic drugmaker Perrigo Co under the condition Mylan sells seven drugs to Alvogen Group Inc  the Federal Trade Commission said on Tuesday.",
        "date": "11042015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 2-FTC approves Mylan's hostile bid for Perrigo with conditions "
    },
    {
        "content": "Mylan NV   embroiled in an increasingly bitter takeover attempt for fellow drugmaker Perrigo Co Plc   posted a better-than-expected quarterly profit on Friday as sales of its generic drugs increased in North America and Europe.",
        "date": "10302015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Mylan profit beats as generic sales jump in North America and Europe "
    },
    {
        "content": "WASHINGTON  Nov 3 Mylan received U.S. antitrust approval for a hostile takeover of Irish-based generic drugmaker Perrigo Co  the Federal Trade Commission said on Tuesday.",
        "date": "11032015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "FTC approves hostile Mylan takeover of Perrigo with conditions "
    },
    {
        "content": "* Shares little changed in light premarket trading   (Adds forecast  details; updates shares)",
        "date": "10302015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 2-Mylan profit beats as generic sales jump in N.America and Europe "
    },
    {
        "content": "Oct 28 Mylan NV said an Israeli district court has ruled against target Perrigo Company Plc's  attempt to block Mylan's listing on the Tel Aviv Stock Exchange.",
        "date": "10282015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Israeli court rules in favour of Mylan's Tel Aviv stock listing "
    },
    {
        "content": "TEL AVIV  Oct 27 The chief executive of Irish-based generic drugmaker Perrigo Co on Tuesday urged shareholders not to accept rival Mylan NV's $25 billion hostile bid for the company.",
        "date": "10272015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo CEO doesn't believe Mylan's hostile bid will succeed "
    },
    {
        "content": "Oct 30 Mylan NV  which has made a hostile bid for Perrigo Co Plc  posted a 29 percent rise in quarterly revenue as demand for its generic drugs increased in North America and Europe.",
        "date": "10302015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan revenue rises 29 percent "
    },
    {
        "content": "Oct 30 Mylan NV  which has made a hostile bid for Perrigo Co Plc  said on Friday that a U.S. district court has denied Perrigo's motion for a preliminary injunction to block the closing of any tender offer.",
        "date": "10302015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan says U.S. court denies Perrigo's motion to block tender offer "
    },
    {
        "content": "Oct 21 A lawyer for Perrigo Co on Wednesday urged a federal judge in Manhattan to stop Mylan NV from moving forward with its unsolicited offer to buy the Michigan-based drugmaker until it corrects what he called misleading statements to Perrigo shareholders.",
        "date": "10212015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo urges judge to put Mylan offer on hold "
    },
    {
        "content": "Perrigo Co Plc  said it would lay off 6 percent of its global workforce and buy back shares worth $2 billion to boost earnings  as the generic drug maker looks to convince investors to rebuff Mylan NV's  hostile bid.",
        "date": "10222015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Perrigo plans job cuts  share buyback as Mylan deadline looms "
    },
    {
        "content": "* Perrigo shares fall as much as 8 pct   (Adds CEO  analyst comments; updates shares)",
        "date": "10222015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 4-Perrigo plans job cuts  share buyback as Mylan deadline looms "
    },
    {
        "content": "Oct 22 Drugmaker Perrigo Co Plc said it would cut about 800 jobs and buy back $2 billion worth of common shares as it looks to stave off a hostile bid from Mylan NV .",
        "date": "10222015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo to cut 800 jobs  buy back $2 bln in shares "
    },
    {
        "content": "Oct 13 The Irish Takeover Panel said on Tuesday that it had rejected Perrigo Company Plc's request to declare Mylan NV's unsolicited tender offer lapsed.",
        "date": "10132015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Irish takeover panel rejects Perrigo's request over Mylan offer "
    },
    {
        "content": "(Adds details  background)     Oct 13 The Irish Takeover Panel said on Tuesday that it had rejected generic drugmaker Perrigo Company Plc's  request to declare Mylan NV's unsolicited tender offer lapsed.     The offer from Mylan remains \"lawful and valid and fully capable of acceptance\" by all Perrigo shareholders including Israeli ones  the takeover panel said.      Netherlands-based Mylan has offered $75 in cash and 2.3 Mylan shares for each Perrigo share  a combination now wort",
        "date": "10132015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 1-Irish takeover panel rejects Perrigo's request over Mylan offer "
    },
    {
        "content": "* Perrigo recently made an application to Panel requesting Panel to declare Mylan's offer of Sept. 14  2015 lapsed",
        "date": "10132015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Irish Takeover Panel rejects Perrigo application to declare Mylan offer lapsed "
    },
    {
        "content": "Some of Perrigo Company Plc's  top shareholders have asked the Irish generic drugmaker to explore a sale  hoping for an alternative to Mylan NV's  roughly $25 billion hostile bid  according to people familiar with the matter.",
        "date": "09292015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Exclusive: Perrigo under shareholder pressure to explore sale \u2013 sources "
    },
    {
        "content": "NEW YORK  Sept 22 Mylan NV countersued Perrigo Company Plc on Tuesday over \"serious misstatements\" it made related to the generic and over-the-counter drugmaker's unsolicited $27 billion tender offer.",
        "date": "09222015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan countersues Perrigo over 'misstatements' about tender offer "
    },
    {
        "content": "NEW YORK  Sept 22 Mylan NV countersued Perrigo Co on Tuesday over \"serious misstatements\" it made as part of its defense against an unsolicited $27 billion tender offer by the generic and over-the-counter drugmaker.",
        "date": "09222015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 1-Mylan countersues Perrigo over 'misstatements' about tender offer "
    },
    {
        "content": "Generic and over-the-counter drugmaker Perrigo Co on Thursday urged its shareholders to reject Mylan NV's unsolicited $27 billion tender offer  saying it substantially undervalued the company.",
        "date": "09172015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo recommends shareholders reject Mylan's tender offer "
    },
    {
        "content": "Sept 17 Generic and over-the-counter drugmaker Perrigo Co on Thursday urged its shareholders to reject Mylan NV's unsolicited $27 billion tender offer  saying it substantially undervalued the company.",
        "date": "09172015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 3-Perrigo recommends shareholders reject Mylan's tender offer "
    },
    {
        "content": "Sept 14 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Monday:",
        "date": "09142015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "Sept 17 Perrigo Co Plc rejected Mylan NV's unsolicited $27 billion tender offer  saying it substantially undervalued the company and did not adequately compensate shareholders.",
        "date": "09172015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo rejects Mylan's tender offer "
    },
    {
        "content": "Sept 14 Mylan NV said it launched a tender offer to acquire fellow generic drugmaker Perrigo Co Plc  for about $27 billion - an offer Perrigo has rejected.",
        "date": "09142015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan launches tender offer for Perrigo "
    },
    {
        "content": "Sept 14 Mylan NV said it launched a tender offer on Monday to acquire fellow generic drugmaker Perrigo Co Plc for about $27 billion - an offer Perrigo has rejected so far.",
        "date": "09142015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 1-Mylan launches tender offer for Perrigo "
    },
    {
        "content": "NEW YORK Mylan NV  shareholders on Friday backed the drugmaker's hostile bid for Perrigo Co   allowing it to launch a tender offer for the company's shares in the next few weeks.",
        "date": "08282015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Mylan shareholders back Perrigo takeover  tender offer up next "
    },
    {
        "content": "NEW YORK  Aug 28 Mylan NV shareholders on Friday backed the drugmaker's hostile bid for Perrigo Co   allowing it to launch a tender offer for the company's shares in the next few weeks.",
        "date": "08282015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 2-Mylan shareholders back Perrigo takeover  tender offer up next "
    },
    {
        "content": "NEW YORK  Aug 28 Mylan NV shareholders on Friday backed the drugmaker's hostile bid for Perrigo Co   allowing it to launch a tender offer for the company's shares in the next few weeks.",
        "date": "08282015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan says shareholders back Perrigo takeover "
    },
    {
        "content": "NEW YORK Perrigo Co Plc's  chief executive expressed confidence on Tuesday that his company's shareholders will reject rival generic drugmaker Mylan NV's hostile takeover attempt  and said the offer is not close to what it would take to get a deal done.",
        "date": "08252015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Perrigo CEO expects shareholders to reject Mylan bid "
    },
    {
        "content": "* Ruled Perrigo's Aug 13 statement \"Mylan already proposed a dilutive deal that substantially undervalues Perrigo\" breached rule",
        "date": "08252015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Irish Takeover Panel says Perrigo's Aug 13 statement breached rule "
    },
    {
        "content": "BRUSSELS  Aug 19 The following are mergers under review by the European Commission and a brief guide to the EU merger process:",
        "date": "08212015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "EU mergers and takeovers (Aug 21) "
    },
    {
        "content": "BRUSSELS  Aug 21 The European Commission cleared on Friday U.S. drugmaker Perrigo's acquisition of certain assets from Britain's GSK.",
        "date": "08212015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "EU Commission clears Perrigo to buy GSK units "
    },
    {
        "content": "NEW YORK  Aug 14 ISS Proxy Advisory Services recommended on Friday that its clients vote against Mylan NV's  $30 billion hostile takeover of Perrigo Co  even as Mylan's largest hedge fund investor put its money behind the combination.",
        "date": "08142015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "UPDATE 2-Proxy firm urges Mylan investors vote 'no'; Paulson backs deal "
    },
    {
        "content": "NEW YORK  Aug 14 ISS Proxy Advisory Services on Friday recommended that its institutional investor clients vote against Mylan NV's $34 billion hostile takeover offer of Perrigo Co saying that it would result in significant dilution.",
        "date": "08142015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Proxy firm ISS advises Mylan investors to vote no on Perrigo buy "
    },
    {
        "content": "NEW YORK Mylan NV   which is trying to buy drugmaker Perrigo Co   through a $34 billion hostile tender offer  on Thursday lowered the percentage of Perrigo shares it needs to control the company to just over 50 percent.",
        "date": "08132015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Mylan pursues minimum of Perrigo shareholder support for takeover "
    },
    {
        "content": "NEW YORK  Aug 13 Mylan NV  which is trying to buy drugmaker Perrigo Co  through a $34 billion hostile tender offer  on Thursday lowered the percentage of Perrigo shares it needs to control the company to just over 50 percent.",
        "date": "08132015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 3-Mylan pursues minimum of Perrigo shareholder support for takeover "
    },
    {
        "content": "NEW YORK  Aug 13 Mylan NV  which is trying to buy drugmaker Perrigo Co  through a hostile tender offer  on Thursday lowered the  level of support it requires from Perrigo shareholders to push through the takeover.",
        "date": "08132015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan pursues Perrigo with lower shareholder support for takeover "
    },
    {
        "content": "Aug 5 Perrigo Co Plc on Wednesday made a fresh case for rejecting a $34 billion offer from generic drugmaker Mylan NV and said Mylan's recent share price plunge reinforces Perrigo's intention to remain independent.",
        "date": "08052015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo CEO says no easy path for Mylan to acquire company "
    },
    {
        "content": "NEW YORK Generic drugmaker Mylan Inc's  chief executive said on Thursday that acquiring Perrigo Co  was not a must and that it has other options should Perrigo successfully fend off  Mylan's $34 billion hostile offer.",
        "date": "08062015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Mylan CEO says still wants Perrigo but has other options "
    },
    {
        "content": "NEW YORK  Aug 6 Generic drugmaker Mylan Inc's  chief executive said on Thursday that acquiring Perrigo Co was not a must and that it has other options should Perrigo successfully fend off  Mylan's $34 billion hostile offer.",
        "date": "08062015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 2-Mylan CEO says still wants Perrigo but has other options "
    },
    {
        "content": "NEW YORK  Aug 6 Generic drugmaker Mylan Inc  's Chief Executive Heather Bresch said Thursday acquiring Perrigo Co was not a must and it had other options besides Perrigo  which has rejected Mylan's $34 billion hostile offer.",
        "date": "08062015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan CEO says has other options  doesn't 'have to' buy Perrigo "
    },
    {
        "content": "Drugmaker Mylan Inc reported a better-than-expected quarterly profit as it sold more generic drugs in North America  and said it remained committed to its acquisition of Perrigo Co Plc.",
        "date": "08062015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "North America generic sales help Mylan's profit beat "
    },
    {
        "content": "Aug 6 Drugmaker Mylan Inc reported a better-than-expected quarterly profit as it sold more generic drugs in North America  and said it remained committed to its acquisition of Perrigo Co Plc.",
        "date": "08062015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 1-North America generic sales help Mylan's profit beat "
    },
    {
        "content": "BRUSSELS  July 30 The following are mergers under review by the European Commission and a brief guide to the EU merger process:",
        "date": "07302015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "EU mergers and takeovers (July 30) "
    },
    {
        "content": "BRUSSELS  July 29 The European Commission said on Wednesday it had cleared generic drug maker Mylan's  planned takeover of Ireland-based Perrigo Co.",
        "date": "07292015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "EU clears acquisition of Perrigo by Mylan "
    },
    {
        "content": "BRUSSELS  July 24 The following are mergers under review by the European Commission and a brief guide to the EU merger process:",
        "date": "07242015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "EU mergers and takeovers (July 24) "
    },
    {
        "content": "BRUSSELS  June 25 European Union competition regulators will decide by July 29 whether U.S. drugmaker Mylan  should be allowed to go ahead with its $34-billion hostile bid for Perrigo  the European Commission said.",
        "date": "06252015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "EU regulators to rule on Mylan bid for Perrigo by July 29 "
    },
    {
        "content": "TEL AVIV  June 24 Drugmaker Mylan NV's  chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange (TASE) if it succeeds in buying Perrigo Co.",
        "date": "06242015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan eyes Tel Aviv listing if Perrigo deal goes ahead "
    },
    {
        "content": "TEL AVIV  June 23 Mylan NV chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying Perrigo Co  an industry source said.",
        "date": "06232015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Mylan CFO to meet Tel Aviv bourse chief to discuss listing - source "
    },
    {
        "content": "TEL AVIV  June 24 Drugmaker Mylan NV's  chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange (TASE) if it succeeds in buying Perrigo Co.",
        "date": "06242015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 1-Mylan eyes Tel Aviv listing if Perrigo deal goes ahead "
    },
    {
        "content": "Mylan NV's  largest stakeholder  Abbott Laboratories   said it would back Mylan's proposed acquisition of Perrigo Co Plc   potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd .",
        "date": "06162015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Abbott to vote for Mylan's acquisition of Perrigo "
    },
    {
        "content": "June 16 Mylan NV's largest stakeholder  Abbott Laboratories  said it would back Mylan's proposed acquisition of Perrigo Co Plc  potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd .",
        "date": "06162015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "REFILE-UPDATE 1-Abbott to vote for Mylan's acquisition of Perrigo "
    },
    {
        "content": "Mylan NV's Chairman Robert Coury said he may sweeten the company's offer for Perrigo Co Plc by adding terms that will reduce risk to Perrigo's shareholders  sources told Bloomberg on Monday.",
        "date": "05122015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Mylan chairman said to consider Perrigo sweeteners to make deal: Bloomberg "
    },
    {
        "content": "May 11 Mylan NV's Chairman Robert Coury said he may sweeten the company's offer for Perrigo Co Plc  by adding terms that will reduce risk to Perrigo's shareholders  sources told Bloomberg on Monday.",
        "date": "05122015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan chairman said to consider Perrigo sweeteners to make deal -Bloomberg "
    },
    {
        "content": "Generic drugmaker Mylan NV   at the center of a high-stakes  three-way takeover battle  said on Tuesday it is fully committed to acquiring Ireland-based Perrigo Co  and believes it can complete the deal by year end.",
        "date": "05052015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Mylan says can close Perrigo deal by year end  reports profit "
    },
    {
        "content": "May 5 Generic drugmaker Mylan NV  at the center of a high-stakes  three-way takeover battle  said on Tuesday it is fully committed to acquiring Ireland-based Perrigo Co and believes it can complete the deal by year end.",
        "date": "05052015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 2-Mylan says can close Perrigo deal by year end  reports profit "
    },
    {
        "content": "May 5   Mylan Sees q2 adjusted eps $0.86 to $0.90",
        "date": "05052015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "BRIEF-Mylan confident it can close Perrigo deal by year end "
    },
    {
        "content": "May 5 Generic drugmaker Mylan NV  at the center of a high-stakes  three-way takeover battle  on Tuesday reported slightly higher-than-expected first-quarter profit and said it was \"steadfast\" in its commitment to acquire Ireland-based Perrigo Co.",
        "date": "05052015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan reports profit  maintains commitment to acquire Perrigo "
    },
    {
        "content": "April 30 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Thursday:",
        "date": "04302015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "Mylan NV  rejected Teva Pharmaceutical Industries Ltd's  $40 billion takeover offer on Monday  saying in a scathing letter that it grossly undervalued the company and that Mylan has no interest in payment in what it termed \"high-risk\" Teva stock.",
        "date": "04272015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Mylan says Teva offer too low; criticizes stock  growth prospects "
    },
    {
        "content": "Generic drugmaker Mylan NV said on Friday it would take its $31 billion offer for Perrigo Co Plc directly to shareholders  in what is set to be one of the most high-profile hostile takeover attempts of the year.",
        "date": "04242015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Generic drugmaker Mylan goes hostile in bid for Perrigo "
    },
    {
        "content": "April 24 Generic drugmaker Mylan NV said on Friday it would take its $31 billion offer for Perrigo Co Plc  directly to shareholders  in what is set to be one of the most high-profile hostile takeover attempts of the year.",
        "date": "04242015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 2-Generic drugmaker Mylan goes hostile in bid for Perrigo "
    },
    {
        "content": "Perrigo Co Ltd  on Wednesday rejected a sweetened takeover offer from Mylan NV   while Teva Pharmaceutical Industries Ltd  said it remains committed to acquiring Mylan  in a high stakes battle of major generic drugmakers.",
        "date": "04292015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Perrigo rejects raised Mylan bid; Teva recommits to Mylan buy "
    },
    {
        "content": "April 24 Generic drugmaker Mylan NV said on Friday it would commence a formal offer to acquire Perrigo Co Plc  three days after Perrigo rejected its unsolicited offer.",
        "date": "04242015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan says to commence offer for Perrigo "
    },
    {
        "content": "* Teva responds to Mylan rejection   (Adds details from Teva letter to Mylan  updates shares)",
        "date": "04292015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 4-Perrigo rejects raised Mylan bid; Teva recommits to Mylan buy "
    },
    {
        "content": "April 29 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Wednesday:",
        "date": "04292015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "Generic drugmaker Mylan NV  plans to make a new offer for Perrigo Co Plc  in the near term  CNBC reported on Wednesday  citing a source familiar with the matter.",
        "date": "04222015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Mylan plans to make new offer for Perrigo: CNBC "
    },
    {
        "content": "April 21 Dublin-based Perrigo Company Plc  said its board unanimously rejected a $205 per share offer from generic drugmaker Mylan NV  saying the bid substantially undervalued the company.",
        "date": "04212015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo rejects $205/share bid from Mylan "
    },
    {
        "content": "Generic drugmaker Perrigo Company Plc > is expected to reject the latest offer made on Wednesday by Mylan NV   according to a person familiar with the matter.",
        "date": "04292015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo expected to reject Mylan's latest offer: source "
    },
    {
        "content": "April 22 Generic drugmaker Mylan NV  plans to make a new offer for Perrigo Co Plc in the near term  CNBC reported on Wednesday  citing a source familiar with the matter.",
        "date": "04222015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan plans to make new offer for Perrigo - CNBC "
    },
    {
        "content": "Perrigo Co Plc is set to reject a $29 billion unsolicited takeover offer from generic drugmaker Mylan NV as soon as this week  according to a source familiar with the matter.",
        "date": "04212015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Exclusive: Perrigo expected to reject Mylan offer as soon as this week - source "
    },
    {
        "content": "April 21 Perrigo Company PLC is set to reject a $29 billion unsolicited takeover offer from generics drugmaker Mylan NV as soon as this week  according to a source familiar with the matter.",
        "date": "04212015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "EXCLUSIVE-Perrigo expected to reject Mylan offer as soon as this week -source "
    },
    {
        "content": "NEW YORK  April 10 (IFR) - Drugmaker Mylan is at risk of dropping back into junk territory if it doesn't strike a perfect balance between bond and equity to finance its proposed US$30bn acquisition of healthcare supplier Perrigo  analysts warned.",
        "date": "04102015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Perrigo acquisition could threaten Mylan's investment grade "
    },
    {
        "content": " ",
        "date": "04212015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Xx "
    },
    {
        "content": "April 21 Perrigo Company PLC is set to reject a $29 billion unsolicited takeover offer from generics drugmaker Mylan NV as soon as this week  according to a source familiar with the matter.",
        "date": "04212015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "EXCLUSIVE-Perrigo exxpected to reject Mylan offer as soon as this week -source "
    },
    {
        "content": "Generic drugmaker Mylan NV has offered to buy Perrigo Co Plc for about $29 billion in cash and stock  a deal that would make Mylan a major player in over-the-counter consumer products and extend its geographic reach.",
        "date": "04082015",
        "name": "Perrigo Company",
        "news_type": "topStory",
        "symbol": "PRGO",
        "title": "Generic drugmaker Mylan offers $29 billion for Perrigo "
    },
    {
        "content": "April 8 Generic drugmaker Mylan NV has offered to buy Perrigo Co Plc for about $29 billion in cash and stock  a deal that would make Mylan a major player in over-the-counter consumer products and extend its geographic reach.",
        "date": "04082015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "UPDATE 3-Generic drugmaker Mylan offers $29 bln for Perrigo "
    },
    {
        "content": "* Fed minutes indicate rate hike in 2015; members differ on month",
        "date": "04082015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "US STOCKS-Wall St ends with modest gains after Fed minutes "
    },
    {
        "content": "NEW YORK  April 8 Perrigo Co Plc's  options attracted an unusually large bullish bet days ahead of an offer from generic drugmaker Mylan NV to buy the company  options data shows.",
        "date": "04082015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Perrigo options attracted large bullish bet ahead of Mylan offer "
    },
    {
        "content": "* Fed minutes indicate rate hike in 2015  but members differ on month",
        "date": "04082015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "US STOCKS-Wall St rises in volatile trading after Fed minutes "
    },
    {
        "content": "* Fed's Dudley keeps June rate hike on the table depending on data",
        "date": "04082015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "US STOCKS-Wall St ticks up on M&A but energy weighs as crude drops "
    },
    {
        "content": "April 8 Generic drugmaker Mylan NV  proposed to buy Perrigo Co Plc for about $29 billion in cash and stock.",
        "date": "04082015",
        "name": "Perrigo Company",
        "news_type": "normal",
        "symbol": "PRGO",
        "title": "Mylan proposes to buy Perrigo for about $29 bln "
    }
]